IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL
UC-GIG-2411
Phase 2 small_molecule active
Quick answer
IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL for Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2) is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active